已收盘 06-08 16:00:00 美东时间
0.000
0.00%
Ev Dynamics (Holdings) Limited ( ($HK:0476) ) has provided an update. Ev Dynami...
11-05 17:09
<p>Concentrix Corporation has launched its proprietary Concentrix Migration Engine for Dynamics 365 Contact Center, an AI-powered application available on Microsoft Marketplace. This patent-pending app accelerates the migration from legacy CX platforms to Microsoft Dynamics 365, reducing migration time by up to 50%. By leveraging agentic AI and automation, the app helps enterprises modernize their customer engagement operations faster and unlock ...
11-05 14:05
Hydrocarbon Dynamics ( ($AU:GBL) ) has shared an announcement. Great Bear Explo...
11-04 06:55
①本季度营收923亿美元,同比增19%,微软云收入639亿美元,同比增长30%; ②Q1资本开支452亿美元,指引Q2资本支出超500亿美元,全年资本开支预计1700亿美元; ③Azure增速达48%,Copilot、Foundry等AI产品用户与付费规模快速提升。
10-29 10:51
微软Q1营收923亿美元增19%、微软云630亿增30%;Q2指引960亿美元,全年资本支出约1700亿美元。
10-29 10:34
微软2027财年第一季度财报电话会:营收增长19%至923亿美元,Azure增长48%,管理层指引第二季度营收为960亿至971亿美元。
10-28 23:39
TradingKey - SanDisk (SNDK) will release its first-quarter fiscal 2027 earnings report after the U.S. market close on October 29, Eastern Time. The company previously issued official guidance projecting revenue between $10.3 billion and $10.8 billion, with adjusted earnings per share of $44 to $46.
10-28 13:32
Fuel Tech, Inc. has secured multiple Air Pollution Control (APC) contract amendments worth approximately $3.3 million for utility and industrial customers. A domestic order involves supplying SCR systems with UDI urea direct injection systems for two natural gas-fired turbines, expanding the scope to include additional equipment. In Europe, three separate SCR projects were awarded. The company's backlog now totals around $20 million, with additio...
10-26 12:30
Solution Dynamics Limited ( ($NZ:SDL) ) just unveiled an announcement. Solution...
10-22 04:49
Jade Biosciences announced at ASN Kidney Week 2026 that three posters on JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, will be presented. The posters highlight the planned acceleration of the EVERGREEN Phase 3 trial, now expected to begin in Q4 2026, and interim data from the ongoing JUNIPER Phase 2 trial, anticipated in Q2 2027. The company expressed confidence in JADE101's potential to achieve sustained IgA reductions with qua...
10-21 11:00